Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study

Karyopharm reported its oncology therapy produced a statistically significant improvement in spleen volume in a late-stage trial for a rare blood cancer, meeting one of the study's primary endpoints. The positive efficacy readout boosts the program's regulatory and commercial prospects and could move the stock by a few percent depending on follow-up data and regulatory guidance.

Analysis

Karyopharm reported its oncology therapy produced a statistically significant improvement in spleen volume in a late-stage trial for a rare blood cancer, meeting one of the study's primary endpoints. The positive efficacy readout boosts the program's regulatory and commercial prospects and could move the stock by a few percent depending on follow-up data and regulatory guidance.